SignalXSignalX

CapsoVision, Inc (CV) 8-K Current Report: March 13, 2026

Filed: March 13, 2026
Health Care
Electromedical & Electrotherapeutic Apparatus
CapsoVision, Inc Overview

CapsoVision, Inc (CV) 8-K current report filed with SEC EDGAR on March 13, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 1.01: Entry into a Material Definitive Agreement

CapsoVision, Inc 8-K Mar 13, 2026 Event Analysis

Item 1.01 · Entry into a Material Definitive Agreement

  • • Total Canon development fee raised to ~$5.1M ($4.1M original + $1M amendment) for CMOS image sensor development
  • • Amendment triggered by expanded feature specifications; all other original terms unchanged
  • • Payment structure: $1M upfront cash, remaining ~$4.1M embedded in per-unit pricing under future master purchase agreement
  • • Strategic dependency: FDA 510(k) clearance for next-gen capsule endoscopy product contingent on Canon delivering sensors to spec
  • • Minimum purchase commitment under master purchase agreement still required — volume obligation unquantified but binding

Get deeper insights on CapsoVision, Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.